Ser105
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser105  -  SPRED1 (human)

Site Information
KFGLTFQsPADARAF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 36131862

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 1 )
Disease tissue studied:
bone cancer ( 1 ) , leukemia ( 1 ) , chronic myelogenous leukemia ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
A431 (epithelial) ( 1 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 2 ) , K562 (erythroid) ( 1 ) , NCI-H1975 (pulmonary) ( 1 ) , PC9 (pulmonary) ( 1 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
EGFR (human) ( 1 )

Downstream Regulation
Effects of modification on SPRED1:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 ) , signaling pathway regulation ( 1 )
Inhibit interaction with:
NF1 (human) ( 1 )

References 

1

Yan W, et al. (2020) Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR. Cell Rep 32, 107909
32697994   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.